MarketCap
Facebook
X
Telegram
Provention Bio Total Assets | PRVB
Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.Main categories of assets
Current assets (used within one year):
- Cash and cash equivalents
- Accounts receivable (amounts owed by customers)
- Inventory of goods, raw materials, and supplies
- Short-term investments
- Fixed assets (buildings, machinery, equipment)
- Intangible assets (brands, patents, software)
- Long-term investments
- Goodwill (reputational value from mergers)
Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.
Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.
Annual Total Assets Provention Bio
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 237 M | 136 M | 129 M | 86 M | 61.5 M | 22.4 M | 125 K | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 237 M | 125 K | 95.9 M |
Quarterly Total Assets Provention Bio
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 194 M | 104 M | 122 M | 136 M | 158 M | 183 M | 214 M | 129 M | 152 M | 176 M | 78.1 M | 86 M | 96.4 M | 42.4 M | 51.9 M | 61.5 M | 66.3 M | 12.2 M | 61.5 M | 22.4 M | 22.4 M | 22.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 214 M | 12.2 M | 99.6 M |
Total Assets of other stocks in the Biotechnology industry
| Issuer | Total Assets | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Repare Therapeutics
RPTX
|
177 M | - | - | $ 112 M |  Canada |
 |
Sesen Bio
SESN
|
30.5 M | - | 7.29 % | $ 127 M |  USA |
 |
Windtree Therapeutics
WINT
|
27.9 M | - | - | $ 26.8 M | USA |
 |
Trean Insurance Group
TIG
|
1.58 B | - | - | $ 316 M | USA |
 |
SQZ Biotechnologies Company
SQZ
|
99.9 M | - | 57.95 % | $ 12.8 M | USA |
 |
MEI Pharma
MEIP
|
42.7 M | - | 10.43 % | $ 20.5 M | USA |
 |
Palatin Technologies
PTN
|
8.52 M | - | - | $ 13 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
1.51 B | - | - | - |  Russia |
 |
Lyra Therapeutics
LYRA
|
36.1 M | - | - | $ 24.9 M | USA |
 |
Brickell Biotech
BBI
|
11.6 M | - | -5.38 % | $ 6.06 M | USA |
 |
Applied Therapeutics
APLT
|
86.7 M | - | - | $ 8.42 M | USA |
 |
ESSA Pharma
EPIX
|
128 M | - | - | $ 8.86 M | Canada |
 |
Generation Bio Co.
GBIO
|
231 M | - | - | $ 344 M | USA |
 |
Clearside Biomedical
CLSD
|
25.1 M | - | - | $ 25.3 M | USA |
 |
Merus N.V.
MRUS
|
783 M | - | - | $ 5.78 B |  Niderland |
 |
RAPT Therapeutics
RAPT
|
240 M | - | - | $ 2.36 B | USA |
 |
Annexon
ANNX
|
278 M | $ 4.2 | -0.71 % | $ 651 M | USA |
 |
AbbVie
ABBV
|
134 B | $ 293.87 | 0.19 % | $ 520 B | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
4.97 B | $ 151.6 | -3.2 % | $ 19.9 B | USA |
 |
Galmed Pharmaceuticals Ltd.
GLMD
|
18.6 M | $ 4.63 | 21.05 % | $ 20 M |  Israel |
 |
Avenue Therapeutics
ATXI
|
2.93 M | - | -52.27 % | $ 4.45 M | USA |
 |
Axon Enterprise
AXON
|
7 B | $ 302.6 | -0.19 % | $ 23.6 B | USA |
 |
Theratechnologies
THTX
|
53.3 M | - | - | $ 83.9 M | Canada |
 |
Liquidia Corporation
LQDA
|
328 M | $ 51.37 | 7.31 % | $ 4.42 B | USA |
 |
CRISPR Therapeutics AG
CRSP
|
2.27 B | $ 45.05 | -9.97 % | $ 4.05 B |  Schweiz |
 |
Scholar Rock Holding Corporation
SRRK
|
404 M | $ 48.48 | -5.96 % | $ 5.56 B | USA |
 |
Geron Corporation
GERN
|
571 M | $ 0.96 | -3.71 % | $ 640 M | USA |
 |
Bristol-Myers Squibb Company
BMY
|
90 B | $ 62.8 | 1.06 % | $ 128 B | USA |
 |
Titan Pharmaceuticals
TTNP
|
2.92 M | - | -3.76 % | $ 3.47 M | USA |
 |
Kazia Therapeutics Limited
KZIA
|
6.06 M | $ 7.4 | -0.13 % | $ 113 M |  Australia |
 |
Celldex Therapeutics
CLDX
|
583 M | $ 30.68 | -1.81 % | $ 2.04 B | USA |
 |
CollPlant Biotechnologies Ltd.
CLGN
|
10.8 M | $ 4.0 | -6.76 % | $ 48.8 M | Israel |
 |
Allena Pharmaceuticals
ALNA
|
34.8 M | - | 3.16 % | $ 1.9 M | USA |
 |
Ligand Pharmaceuticals Incorporated
LGND
|
1.56 B | $ 317.26 | 0.99 % | $ 6.14 B | USA |
 |
Eli Lilly and Company
LLY
|
112 B | $ 1 432.7 | 1.47 % | $ 1.29 T | USA |
 |
TCR2 Therapeutics
TCRR
|
208 M | - | - | $ 58.1 M | USA |
 |
Crinetics Pharmaceuticals
CRNX
|
1.13 B | $ 84.95 | 0.13 % | $ 7.99 B | USA |
|
TFF Pharmaceuticals
TFFP
|
12 M | - | -60.05 % | $ 125 K | USA |
 |
Mesoblast Limited
MESO
|
785 M | $ 14.0 | -3.06 % | $ 16.9 B | Australia |
 |
CorMedix
CRMD
|
826 M | $ 5.37 | -2.1 % | $ 387 K | USA |
 |
Adaptimmune Therapeutics plc
ADAP
|
246 M | - | -15.15 % | $ 60.3 M |  Britain |
 |
MannKind Corporation
MNKD
|
792 M | $ 4.22 | 0.84 % | $ 1.29 B | USA |
 |
AVEO Pharmaceuticals
AVEO
|
105 M | - | - | $ 521 M | USA |
 |
MediciNova
MNOV
|
45.6 M | $ 1.4 | -4.76 % | $ 68.7 M | USA |
 |
Merck & Co.
MRK
|
137 B | $ 147.75 | -0.68 % | $ 370 B | USA |
 |
Moderna
MRNA
|
12.3 B | $ 250.79 | -6.77 % | $ 97.6 B | USA |
 |
Axcella Health
AXLA
|
18.9 M | - | -16.42 % | $ 249 M | USA |